Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301,a nanoparticle of docetaxel  

作　　者：Eiman Mukhtar Daniel Worroll Giuseppe Galletti Shelly Schuster Sarina A.Piha-Paul Paraskevi Giannakakou 

机构地区：[1]Department of Medicine,Hematology/Oncology,Weill Cornell Medicine,New York,NY 10065,USA. [2]Sandra and Edward Meyer Cancer Center,Department of Medicine,Weill Cornell Medicine,New York,NY 10065,USA. [3]NewLink Genetics Corporation,Ames,IA 50010,USA. [4]The University of Texas,MD Anderson Cancer Center,Houston,TX 77030,USA.

出　　处：《Cancer Drug Resistance》2020年第3期636-646,共11页癌症耐药（英文）

摘　　要：Aim:We reviewed the radiographic response of three patients with metastatic castration-resistant prostate cancer treated with CRXL301,a docetaxel nanoparticle.For these three patients,we isolated and analyzed circulating tumor cells(CTCs)to explore microtubule(MT)drug-target engagement(MT-DTE)as a biomarker of response to treatment.MT-DTE was based on a quantitative assessment of the MT cytoskeleton in CTCs from pre-and posttreatment patient samples as a potential read-out of CRXL301 activity.Methods:We isolated CTCs using negative CD45+depletion and subjected them to multiplex confocal microscopy using our established protocol.CTCs were identified as CD45-/CK+/DAPI+cells and MT-DTE was determined using our developed imaging algorithm.We quantified MT bundling in CTCs across multiple time points,from baseline to on-treatment to disease progression.Here,we describe the longitudinal analysis of MT-DTE in CTCs from patients treated with CRXL301 and its correlation with response to treatment.Results:We collected CTCs at seven time points from three metastatic castration-resistant prostate cancer patients.Clinical response was evaluated by Response Evaluation Criteria in Solid Tumors(RECIST)v.1.1 criteria in those patients with measurable disease.Of the three patients enrolled,one experienced partial response(-50%)to CRXL301 and two patients were unevaluable given bone only disease.Notably,however,these two patients showed stable disease clinically based on bone scans.MT-DTE across all time points revealed that,early time points within four and 24 h of drug administration exhibited the highest levels of drug engagement(MT-DTE)as compared to baseline.However,these early time points did not correlate with clinical response.We observed that the CTCs collected one week after the first or second dose of CRXL301 treatment in the responding patient had numerically higher levels of MT-DTE as compared to the other two patients.Conclusion:Taxane on-target activity can be detected and analyzed quantitatively in CTCs by tubulin i

关 键 词：Liquid biopsy circulating tumor cells castration-resistant prostate cancer MICROTUBULES TAXANES biomarkers 

分 类 号：R73[医药卫生—肿瘤]